Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Cataldi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
BMC Musculoskeletal Disorders|December 17, 2025
A population-based survey of beliefs about neck pain and its associated disorders: a cross-sectional studyMirella Forte, Federica Nasti, Stefano Schiavone, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gut|January 9, 2015
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Julián Panés, Sunil Khurana, et al.
Neurogastroenterology and Motility|February 6, 2023
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)Lin Chang, Brooks D Cash, Anthony Lembo, et al.
Journal of Crohn'S & Colitis|November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's DiseaseMina Hassan-Zahraee, Anindita Banerjee, John B Cheng, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
BMC Musculoskeletal Disorders|December 17, 2025
A population-based survey of beliefs about neck pain and its associated disorders: a cross-sectional studyMirella Forte, Federica Nasti, Stefano Schiavone, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Gut|January 9, 2015
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Julián Panés, Sunil Khurana, et al.
Neurogastroenterology and Motility|February 6, 2023
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)Lin Chang, Brooks D Cash, Anthony Lembo, et al.
Journal of Crohn'S & Colitis|November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's DiseaseMina Hassan-Zahraee, Anindita Banerjee, John B Cheng, et al.
Pageof 3